Search

Your search keyword '"Natoli, C."' showing total 683 results

Search Constraints

Start Over You searched for: Author "Natoli, C." Remove constraint Author: "Natoli, C."
683 results on '"Natoli, C."'

Search Results

1. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

2. Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

4. Variational study of the antiferromagnetic insulating phase of V2O3 based on Nth order Muffin-Tin-Orbitals

5. Structural dichroism in the antiferromagnetic insulating phase of V_2O_3

6. The implications of resonant x-ray scattering data on the physics of the insulating phase of V_2O_3

7. A critical reexamination of the non-reciprocal x-ray gyrotropy in V_2O_3

8. Observation of local chiral-symmetry breaking in globally centrosymmetric crystals

9. Spin-1 effective Hamiltonian with three degenerate orbitals: An application to the case of V_2O_3

10. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience

12. Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

13. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

14. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

15. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

16. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

17. Unknown primary tumors

19. C25 - Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

20. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations

21. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

22. Long-term outcome of pemetrexed maintenance for advanced nonsquamous non-small-cell lung cancer: A real-world observational cohort study [Risultati a lungo termine della terapia di mantenimento con pemetrexed nei pazienti affetti da tumore polmonare non a piccole cellule in stadio avanzato e istologia non squamosa: Uno studio osservazionale di coorte condotto nella pratica clinica del mondo reale]

24. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

25. Additional file 14 of MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

26. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

27. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

28. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

29. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

30. Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

31. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

34. P-168 Second-line, anti-VEGF based after first-line, anti-EGFR based treatment in RAS wild-type metastatic colorectal cancer: The multicenter, retrospective, real-life SLAVE study

35. Corrigendum to “Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation”

36. Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study

37. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

38. Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts

41. Molecular tilting and columnar stacking of Fe phthalocyanine thin films on Au(111).

43. Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation

44. Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study

45. Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study

46. A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy

47. Abstract P4-13-04: Not presented

50. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Catalog

Books, media, physical & digital resources